Compare ISPC & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISPC | OGEN |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.2M |
| IPO Year | 2020 | 2010 |
| Metric | ISPC | OGEN |
|---|---|---|
| Price | $0.92 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 104.7K | 22.6K |
| Earning Date | 11-16-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,928,998.00 | N/A |
| Revenue This Year | $638.10 | N/A |
| Revenue Next Year | $17.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $0.43 |
| 52 Week High | $115.00 | $1.45 |
| Indicator | ISPC | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 23.43 | 37.01 |
| Support Level | N/A | N/A |
| Resistance Level | $1.15 | $0.59 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 2.94 | 0.00 |
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.